The FDA has granted Breakthrough Therapy designation to setrusumab to reduce fracture risk with osteogenesis imperfecta type I, III, or IV.

In a 12-month period before and after erenumab use, patients with chronic migraine decreased HRU and use of acute and traditional migraine preventive medications.

After inguinal hernia repair surgery, risk for persistent postoperative pain was increased by several factors.

For patients with rheumatoid arthritis (RA), urine albumin-to-creatinine ratio (ACR) is an independent risk factor indicating prognosis.